Allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-haploidentical related donor using reduced dose of posttransplantation high-dose cyclophosphamide (PTCy) for poor prognosis or refractory hematological malignancies (OCU16-2) - HLA-haploidentical HSCT with reduced dose of PTCy (OCU16-2)

Osaka City University0 sites33 target enrollmentFebruary 8, 2017

Overview

Phase: 未知
Intervention: Not specified
Conditions: Acute myeloid leukemia(AML) Acute lymphoblastic leukemia(ALL) Acute leukemias of ambiguous lineage Myelodysplastic syndrome(MDS) Chronic myeloid leukemia(CML) Adult T-cell leukemia/lymphoma(ATLL) Malignant lymphoma(ML)
Sponsor: Osaka City University
Enrollment: 33
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

February 8, 2017

End Date

April 30, 2021

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\) Major organ dysfunction a) Total bilirubin: \>\= 2\.0 mg/dl b) Serum creatinine: \>\= 2\.0 mg/dl c) Left ventricular ejection fraction: \< 50% d) Pulmonary function test: %VC \<40%, FEV1\.0% \<50% or SaO2 \<90% on room air e) AST or ALT \>\= 3 x UNL 2\) Uncontrolled active infection 3\) Uncontrolled CNS invasion 4\) Poorly controlled insulin\-treated diabetes mellitus 5\) Poorly controlled hypertension 6\) Patients with a severe complication including heart failure, coronary failure, acute myocardial infarction within the last three months, liver cirrhosis and interstitial pneumonia 7\) Pregnant, lactating woman or woman of childbearing potential 8\) Patients with a severe mental disorder who are likely to be unable to participate in the study 9\) A history of hypersensitivity or allergy to any drugs in the conditioning regimen of this transplant 10\) HIV antibody positivity 11\) A history of administration of mogamulizumab 12\) The physician in charge determines that there is no indication to perform this intervention (Note: HBs antigen positivity and HCV antibody positivity is not exclusion criterion)